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Abstract Oligo(nucleoside phosphorothioate)s (S-ODNs), if
prepared by conventional methods, consist of a mixture of dia-
stereomers by virtue of the asymmetry of the phosphorus atom
involved in the internucleotide linkages. This may a¡ect the
stability of the complexes formed between S-ODNs and com-
plementary oligoribonucleotides, which is commonly accepted as
the most important factor in determining the e⁄cacy of an
antisense approach. Using HIV-1-infected MOLT-4 cells via a
long-term culture approach, we studied the in£uence of the
P-chirality sense of stereode¢ned 28mer oligo(nucleoside phos-
phorothioate)s, [All-Rp]-S-ODN-gag-28-AUG and [All-Sp]-S-
ODN-gag-28-AUG, complementary to the sequence starting
at the AUG initiation codon of the gag mRNA of HIV-1,
upon the anti-HIV-1 activity. The [All-Sp]-S-ODN-gag-28-
AUG at a low concentration of 0.5 WM can completely suppress
HIV-1gag p24 antigen expression in HIV-1-infected MOLT-4
clone 8 cells for 32 days. Cells treated with [All-Rp]-S-ODN-
gag-28-AUG (0.5 WM) showed a high level of the antigen ex-
pression at day 16. Furthermore, satisfactory suppression could
not be achieved from a random [Mix]-S-ODN-gag-28-AUG,
consisting of a diastereomeric mixture of the oligonucleotides.
Our results suggest that chemotherapy based upon the use of
stereode¢ned antisense [All-Sp] S-ODN may be a more e¡ective
method for reducing the viral burden in HIV-1-infected
individuals. = 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Oligonucleotides with a phosphorothioate backbone (S-
ODNs) exhibit several advantages over natural ODNs, includ-
ing enhanced nuclease resistance and the ability to induce the
degradation of the targeted RNA sequence by RNase H [1^8].
Numerous S-ODNs are under evaluation as potential drugs
against viruses, cancer and other diseases. However, all of the
oligo(nucleoside phosphorothioate)s being studied, including
[Mix]-S-ODNs, consist of random mixtures of diastereomers,
by virtue of the asymmetry of the phosphorus atom involved
in each internucleotide phosphorothioate linkage [9]. As such,
they undergo nuclease-assisted degradation, primarily by plas-
ma 3P-exonucleases. We have demonstrated that a human
plasma 3P-exonuclease is highly stereoselective towards inter-
nucleotide [Rp]-phosphorothioates [10], and cleaves them at a
rate comparable to that of natural oligonucleotides. There-
fore, all fractions of a diastereomeric mixture with 3P-terminal
[Rp]-phosphorothioates undergo hydrolysis. Moreover, the
stereoselective action of numerous endonucleases on S-
ODNs cannot be excluded [11]. The consequences of this deg-
radation are numerous, since in addition to losing the integ-
rity of the antisense construct, which should work in a cata-
lytic manner, the released nucleoside 5P-phosphorothioates
contaminate the cell with unpredictable e¡ects [12]. Therefore,
several researchers have focused upon either the separation of
diastereomers via reverse phase^high-performance liquid
chromatography [13,14], or the design of stereocontrolled
methods of the synthesis of oligo(nucleoside phosphoro-
thioate)s with a predetermined sense of chirality at the phos-
phorus of each internucleotide phosphorothioate linkage
[15,16]. Beyond the elaborate enzyme-assisted methods pro-
viding [All-Rp]-S-ODNs [17,18], so far the most e¡ective
seems to be the oxathiaphospholane method designed by
our groups [10,19].
In the absence of a practical technology providing stereo-
de¢ned oligo(nucleoside phosphorothioate)s, examples of bio-
logical studies performed with stereode¢ned compounds are
not abundant [20,21]. On the other hand, several publications
have documented the suitability of S-ODNs for anti-HIV-
1[22^26] and anti-in£uenza virus [27^31] applications. In par-
ticular, we ¢rst succeeded in the treatment of in£uenza in an
experimental infectious mouse model of in£uenza A virus,
using S-ODNs [30,31]. We also demonstrated their e¡ective-
ness as inhibitors of HIV-1 replication in an acute-infection
assay [24,32].
In this paper we describe the in£uence of the P-chirality
sense of stereode¢ned oligo(nucleoside phosphorothioate)s
([All-Rp]-S-ODN-gag-28-AUG) and ([All-Sp]-S-ODN-gag-
28-AUG) on the anti-HIV-1 activity in long-term cultures
using HIV-1-infected MOLT-4 clone 8 cells.
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2. Materials and methods
2.1. Oligonucleotides
Random [Mix]-S-ODNs, consisting of a diastereomeric mixture of
the phosphorothioate oligonucleotides, was purchased from Boston
Biosystems, Boston, MA, USA. The synthesis of stereode¢ned oligo-
(nucleoside phosphorothioate)s was performed manually [10,19]. The
¢rst nucleoside units were anchored to the solid support by a sarco-
sinyl linker. Appropriately protected monomers possessing a 3P-O-
(2-thio-‘spiro’-4,4-pentamethylene-1,3,2-oxathiaphospholane) moiety
were synthesized and separated chromatographically into pure diaster-
eomers. The positions of the selected oligonucleotides along the
HIV-1 sequence were 786^813 (S-ODN-gag-28-AUG-as), 5809^5836
(S-ODN-tat-28-sa-as), and 6006^6033 (S-ODN-rev-28-AUG-as)
(Fig. 1).
2.2. Cells and virus
The human T lymphotropic virus type I (HTLV-I)-positive human
T-cell line, MT-4, and the HTLV-I-non-infected T-cell line, MOLT-4
clone 8, were grown and maintained in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), 100 WU/
ml penicillin, and 100 Wg/ml of streptomycin. A strain of HIV-1IIIB,
was obtained from the culture supernatant of chronically HIV-1IIIB-
infected MOLT-4 clone 8 cells, MOLT-4 clone 8/HIV-1IIIB cells, and
was stored in a small volume at 380‡C until use. The titer of the virus
stocks was determined by 50% tissue culture infectious doses
(TCID50).
2.3. Anti-HIV assay
The CD4þ T-cell line, MOLT-4 clone 8 (3U105 ml31), was infected
with HIV-1IIIB at a MOI of 0.01. After a 2 h infection, the cells were
then washed to remove the virus from the medium, and treated with
the synthetic oligonucleotides at 0.5^2.5 WM concentrations in the
culture medium. After 2 days the medium was removed and fresh
medium containing the oligonucleotides at 0.5^2.5 WM concentration
was added. Virus replication was monitored at the cellular level by
syncytia formation and in the culture supernatants by a p24 enzyme-
linked immunosorbent assay (Cellular Products). At the time points
indicated, an aliquot of the culture supernatant was removed for p24
antigen analysis and was replaced by fresh medium. Every 4 days,
viable cells were counted and passed at 3U105 cells per ml [33].
2.4. The indirect immuno£uorescence (IF) assay
The number of HIV-1-speci¢c antigen positive cells was counted by
the indirect IF assay every 4 days. The methanol-¢xed cells were
reacted with anti-HIV-1 human serum for 30 min and then with £uo-
rescing isothiocyanate-conjugated anti-human immunoglobulin G
(Santa Cruz Biotech., USA) for 30 min at 37‡C. More than 500 cells
were counted under a £uorescence microscope, and the percentage of
IF-positive cells was calculated [34].
3. Results and discussion
In a previous study, we demonstrated the e¡ects of a stereo-
de¢ned S-ODN [35]. The results of the RNase H-catalyzed
cleavage of RNA indicated that the DNA^RNA duplexes
containing All-Rp-S-ODN are better substrates for RNase
H than those containing [Mix]-S-ODN or All-Sp-S-ODN,
although the extent of degradation seems to be dependent
upon the length and the primary and secondary structures
of the RNA substrate [35]. Furthermore, the a⁄nity of the
All-Rp-S-ODN towards the complementary RNA was higher
(Tm) than those of the All-Sp-S-ODN and [Mix]-S-ODN,
although it was still lower than that of the ODN. With these
observations in mind, it was tempting to study the in£uence of
the P-chirality sense of the S-ODNs upon their antiviral ac-
tivity.
In previous studies, the random mixtures of diastereomers
S-ODNs complementary to the gag mRNA containing the
AUG initiation codon sequence were more e¡ective inhibitors
of HIV-1 replication than those targeted to the splice-acceptor
site of the tat gene and the AUG initiation codon of the rev
gene in acutely infected cells [32]. Thus, we evaluated the anti-
HIV-1 activity by the inhibition of virus-speci¢c antigen ex-
pression in long-term HIV-1IIIB-infected MOLT-4 clone 8 cells
treated with three di¡erent target oligonucleotides ([Mix]-S-
ODN-gag-28-AUG-as, [Mix]-S-ODN-tat-28-sa-as, and [Mix]-
S-ODN-rev-28-AUG-as). We also chose a random sequence
as the control oligonucleotide ([Mix]-S-ODN-28-ran). The
MOLT-4 clone 8 (3U105 ml31) cells were incubated with
HIV-1IIIB at an MOI of 0.01 for 2 h to allow absorption
[33]. The cells were then washed to remove the virus from
the medium, and the oligonucleotides (1 WM) were added
with fresh medium. After 2 days, new medium supplemented
with the oligonucleotides was added. The virus production in
the culture supernatant was monitored by the HIV-1gag p24
antigen assay (Fig. 2). In this assay system, the phosphoro-
thioate-modi¢ed oligonucleotides cannot interfere with retro-
viral binding at the CD4-receptor, because the cells were in-
cubated with an infectious HIV-1 supernatant for 2 h before
the application of the oligonucleotides. The expression of
HIV-1gag p24 antigen was not detectable during the ¢rst
6 days after HIV-1 infection. However, Fig. 2 shows that
30 days after infection, a high level of HIV-1gag p24 antigen
Fig. 1. Sequences of antisense and control oligo(nucleoside phosphorothioate)s used in this study and the target genes in the genomic structure
of HIV-1. The positions of the selected oligonucleotides along the HIV-1 sequence were 786^813 (S-ODN-gag-28-AUG-as), 5809^5836 (S-
ODN-tat-28-sa-as), and 6006^6033 (S-ODN-rev-28-AUG-as).
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expression was detected in the cultures treated with the ran-
dom oligonucleotide ([Mix]-S-ODN-28-ran), demonstrating
that this control oligonucleotide failed to inhibit HIV-1 repli-
cation. The inhibition of HIV-1gag p24 antigen expression in
cultures treated by the other oligonucleotides was s 90% as
compared with that of the random oligonucleotide. In partic-
ular, the suppression of HIV-1gag p24 antigen expression by
the [Mix]-S-ODN-gag-28-AUG-as and [Mix]-S-ODN-rev-28-
AUG-as oligonucleotides in long-term HIV-1IIIB-infected
MOLT-4 clone 8 cells for 30 days was s 99% as compared
with that of the random oligonucleotide. In contrast, the long-
term treatment (32 days) with [Mix]-S-ODN-tat-28-sa-as still
permitted the HIV-1gag p24 antigen expression. The number
of HIV-speci¢c antigen-positive cells was counted by the in-
direct IF method at 4 day intervals [34]. The IF assay showed
similar results to those of the HIV-1gag p24 antigen assay,
32 days after infection.
Next, we investigated the antiviral activity e¡ects of the
stereode¢ned S-ODNs, composed either of [All-Rp]- or [All-
Sp]-diastereomers. In this assay, we chose the [All-Rp]-S-
ODN-gag-28-AUG-as, and the [All-Sp]-S-ODN-gag-28-
AUG-as, which encode sequences directly adjacent to the
complementary target sequence on the gag mRNA (776^
803) containing the AUG initiation codon from HIV-1IIIB.
The synthesis of stereode¢ned oligo(nucleoside phosphoro-
thioate)s was performed manually [10,19]. The ¢rst nucleo-
side units were anchored to the solid support by a sarcosinyl
linker. Appropriately protected monomers possessing a 3P-O-
(2-thio-‘spiro’-4,4-pentamethylene-1,3,2-oxathiaphospholane)
moiety were synthesized and separated chromatographically
into pure diastereomers. We also chose [Mix]-S-ODN-gag-
28-AUG-as, consisting of the random mixture of diastereom-
ers, and a random sequence ([Mix]-S-ODN-28-ran), as the
control oligonucleotide. The virus production in the culture
supernatant was monitored by the HIV-1gag p24 antigen assay
(Fig. 3A^C).
The control-infected cells (maintained in the absence of
oligonucleotides) showed a high level of HIV-1 replication
at 12 days after infection (Fig. 3A^C). In the cells treated
with the [All-Sp]-S-ODN-gag-28-AUG-as, [Mix]-S-ODN-
gag-28-AUG-as, and [Mix]-S-ODN-28-ran (1 WM), the HIV-
1gag p24 antigen expression was completely suppressed, as
compared to the untreated control cells (Fig. 3B). However,
the cells treated with [All-Rp]-S-ODN-gag-AUG-28-as
showed a high level of HIV-1gag p24 antigen expression at
16 days after infection. In contrast, the cells treated with
[All-Sp]-S-ODN-gag-AUG-28-as completely suppressed the
HIV-1gag p24 antigen expression for 32 days. At day 28,
[Mix]-S-ODN-gag-28-AUG-as showed even greater inhibition
of the HIV-1gag p24 antigen expression, by 99.9%; however, at
32 days after infection, a very low level of HIV-1gag p24 anti-
gen was detected, indicating that [Mix]-S-ODN-gag-AUG-28-
as was less e¡ective than [All-Sp]-S-ODN-gag-28-AUG-as.
Somewhat higher activity was also observed for the diastereo-
meric mixture oligonucleotide, [Mix]-S-ODN-gag-28-AUG-as,
than for [All-Rp]-S-ODN-gag-AUG-28-as. In this case, the
e¡ect of the nuclease stability prevailed over the e¡ect of
the enhanced RNase H activation. We observed earlier that
the rate of RNase H-assisted cleavage of mRNA involved in
the duplex formed by oligo(nucleoside phosphorothioate)s
and the complementary mRNA depends upon the chirality
sense of the involved phosphorothioates [35]. The present re-
sults suggest that the stereodi¡erentiated stability of the phos-
Fig. 2. Comparison of the antiviral activities of three di¡erent target
oligonucleotides ([Mix]-S-ODN-gag-28-AUG-as, [Mix]-S-ODN-tat-
28-sa-as, and [Mix]-S-ODN-rev-28-AUG-as, (mixture of diastereom-
ers)) prepared via non-stereocontrolled methods, at a 1 WM concen-
tration in a long-term assay. Sequence-speci¢c anti-HIV-1 activities
of the [Mix]-S-ODN-gag-28-AUG-as, [Mix]-S-ODN-tat-28-sa-as, and
[Mix]-S-ODN-rev-28-AUG-as, (mixture of diastereomers), compared
to the random oligonucleotide, [Mix]-S-ODN-28-ran, 32 days after
infection. Indirect IF method.
Fig. 3. Antiviral activities of stereoregular S-ODNs ([All-Rp]-(S-ODN-gag-AUG-28-as) and [All-Sp]-28mer) at di¡erent concentrations
(A: 0.5 WM, B: 1.0 WM, and C: 2.5 WM) in long-term cultures using HIV-1-infected MOLT-4 clone 8 cells. Di¡erences in antiviral activities be-
tween antisense phosphorothioate oligonucleotides composed either of a mixture of 227 diastereomers ([Mix]-S-ODN-gag-AUG-28-as) at each
position, or of [All-Rp]-S-ODN-gag-AUG-28-as or [All-Sp]-S-ODN-gag-AUG-28-as diastereomers, 32 days after infection.
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phorothioate oligonucleotides against 3P-exonucleases enhan-
ces the potency of the antisense oligonucleotides. The indirect
IF assay showed similar results (HIV-1-Ag-positive cells :
[Mix]-S-ODN-gag-AUG-28-as, 0%; [All-Sp]-S-ODN-gag-
AUG-28-as, 0%: [All-Rp]-S-ODN-gag-AUG-28-as, 49%;
[Mix]-S-ODN-28-ran, 51%), 28 days after infection. In con-
trast, at a low concentration of 0.5 WM, the cells treated with
[All-Sp]-S-ODN-gag-AUG-28-as completely suppressed the
HIV-1gag p24 antigen expression for 32 days (Fig. 3A). How-
ever, the cells treated with [Mix]-S-ODN-gag-28-AUG-as ex-
pressed the HIV-1gag p24 antigen at 24 days after infection,
also indicating that [Mix]-S-ODN-gag-AUG-28-as was less
e¡ective than [All-Sp]-S-ODN-gag-28-AUG-as (Fig. 3A). On
the other hand, at a high concentration of 2.5 WM, [Mix]-S-
ODN-28-ran and [All-Rp]-S-ODN-gag-AUG-28-as had inhib-
itory e¡ects on the HIV-1gag p24 antigen expression, as com-
pared to the untreated control at 32 days (Fig. 3C). These
results indicate that at high concentrations, the random se-
quence phosphorothioate oligonucleotides may have a non-
sequence-speci¢c antiviral e¡ect, which delays virus replica-
tion, but does not inhibit it e¡ectively. On the other hand,
the exonuclease resistance conferred by the presence of inter-
nucleotide bonds of the Rp con¢guration, as demonstrated
with [All-Sp]-S-ODN-gag-28-AUG-as, enhances the potency
of this antisense oligonucleotide.
In conclusion, the 28mer oligo(nucleoside phosphoro-
thioate)s directed to the gag and rev mRNAs ([Mix]-S-
ODN-gag-28-AUG-as and [Mix]-S-ODN-rev-28-AUG-as), at
a 1 WM concentration, can completely suppress the HIV-1gag
p24 antigen expression in long-term HIV-1IIIB-infected
MOLT-4 clone 8 cells for 30 days (Fig. 2). Essentially, all
of the phosphorothioate oligonucleotides applied thus far in
the antisense methodology were synthesized either by phos-
phoramidite or H-phosphonate methods, and thus consisted
of 2n diastereomers, where n is the number of phosphoro-
thioate bonds [9]. We investigated the stability of stereoregu-
lar phosphorothioate oligonucleotides in human plasma [10].
The [All-Sp]-phosphorothioate oligonucleotides were the most
resistant towards nucleases, followed by the random diaster-
eomeric mixture and the [All-Rp]-phosphorothioate oligonu-
cleotides, with the lowest nuclease resistance [10]. Here we
have demonstrated the e¡ect of the P-chirality sense of stereo-
de¢ned phosphorothioate oligonucleotides ([All-Rp]-S-ODN-
gag-AUG-28-as- and ^[All-Sp]-28mer) on the inhibition of
HIV-1 replication in long-term cultures, using HIV-1-infected
MOLT-4 clone 8 cells. The cells treated with [All-Sp]-S-ODN-
gag-AUG-28-as completely suppressed the HIV-1gag p24 anti-
gen expression for 32 days. In contrast, the cells treated with
[All-Rp]-S-ODN-gag-AUG-28-as showed a high level of HIV-
1 replication. The random mixture of diastereomers, [Mix]-S-
ODN-gag-AUG-28-as, more e¡ectively inhibited the HIV-1gag
p24 antigen expression than [All-Rp]-S-ODN-gag-AUG-28-as.
The protection of the phosphorothioate oligonucleotide from
exonucleases by means of stereochemical control, as demon-
strated with the compound [All-Sp]-S-ODN-gag-28-AUG-as,
enhances the potency of this antisense oligonucleotide and
thus supports the hypothesis that the stability against exo-
and endonucleases is among the most important factors for
the e⁄cacy of antisense oligonucleotides in long-term HIV-
1IIIB-infected MOLT-4 clone 8 cells. The antisense phospho-
rothioate oligonucleotides containing the Sp-con¢guration at
the phosphorus of each internucleotide phosphorothioate
linkage may yield important theoretical and clinical insights
into the regulation of HIV-1 replication.
Acknowledgements: This work was supported in part by a Grant-in-
Aid for High Technology Research from the Ministry of Education,
Science, Sports, and Culture, Japan, a Grant from the Japan Society
for the Promotion of Science in the ‘Research for the Future’ program
(JSPS-RFTF97L00593), a Research Grant from the Human Science
Foundation (HIV-K-1031), and a Grant from the Polish State Com-
mittee for Scienti¢c Research (KBN) (Z-KBN 005/T09/99).
References
[1] Wickstrom, E. (Ed.) (1998) Clinical Trials of Genetic Therapy
with Antisense DNA and DNA Vectors, Marcel Dekker, New
York.
[2] Phillips M.I. (Ed.) (2000): Methods in Enzymology, Vol. 314,
Academic Press, San Diego.
[3] Bennet, C.F., Butler, M., Cook, D., Greary, R.S., Levin, A.A.,
Metha, R., Teng, C.-L., Deshmukh, H., Tillman, L., and Hardee,
G. (2000) in: Gene Therapy, Therapeutic Mechanisms and Strat-
egies (Templeton, N.S., and Lasic, D.D., Eds.), pp. 305^332,
Marcel Dekker, New York.
[4] Inoue, H., Hayase, Y., Iwai, S. and Ohtsuka, E. (1987) FEBS
Lett. 215, 327^330.
[5] Wemmer, D.E. and Benight, A.S. (1985) Nucleic Acids Res. 13,
8611^8621.
[6] Chiang, M.Y., Chan, H., Zounes, M.A., Freier, S.M., Lima,
W.F. and Bennett, C.F. (1991) J. Biol. Chem. 266, 18162^18171.
[7] Wagner, R.W., Matteucci, M.D., Lewis, J.G., Gutierrez, A.J.,
Moulds, C. and Froehler, B.C. (1993) Science 260, 1510^1513.
[8] Dean, N.M. and Mckay, R. (1994) Proc. Natl. Acad. Sci. USA
91, 11762^11766.
[9] Stec, W.J. and Wilk, A. (1994) Angew. Chem. Int. Ed. Engl. 33,
709^722.
[10] Koziolkiewicz, M., Wojcik, M., Kobylanska, A., Karwowski, B.,
Rebowska, B., Guga, P. and Stec, W.J. (1997) Antisense Nucleic
Acid Drug Dev. 7, 43^48.
[11] Koziolkiewicz, M., Owczarek, A., Domanski, K., Nowak, M.,
Guga, P. and Stec, W.J. (2001) Bioorg. Med. Chem. 9, 2403^
2409.
[12] Koziolkiewicz, M., Gendaszewska, E., Maszewska, M., Stein,
C.A. and Stec, W.J. (2001) Blood 98, 995^1002.
[13] Stec, W.J., Zon, G. and Uznanski, B. (1985) J. Chromatogr. 326,
263^280.
[14] Thorogood, H. and Grasby, J.A. (1996) J. Biol. Chem. 271,
8855^8862.
[15] Wang, J.C. and Just, G. (1999) J. Org. Chem. 64, 8090^8097.
[16] Wilk, A., Grajkowski, A., Phillips, L.R. and Beaucage, S.L.
(2000) J. Am. Chem. Soc. 122, 2149^2156.
[17] Hacia, J.G., Wold, B.J. and Dervan, P.B. (1994) Biochemistry 33,
5367^5369.
[18] Lackey, D.B. and Patel, J. (1997) Lett. Biotechn. 19, 475^478.
[19] Stec, W.J., Karwowski, B., Boczkowska, M., Guga, P., Kozio-
kiewicz, M., Sochacki, M., Wieczorek, M.W. and Aszczyk, J.B.
(1998) J. Am. Chem. Soc. 120, 7156^7167.
[20] Fearon, K.L., Hirschbein, B.L., Chiu, C.Y., Quijano, M.R. and
Zon, G. (1997) Chiba Found. Symp. 209, 19^31.
[21] Stec, W.J., Cierniewski, C.S., Okruszek, A., Kobylanska, A.,
Pawlowska, Z., Koziolkiewicz, M., Pluskota, E., Maciaszek, A.,
Rebowska, B. and Stasiak, M. (1997) Antisense Nucleic Acid
Drug Dev. 7, 567^573.
[22] Matsukura, M.K., Shinozuka, K., Zon, G., Mitsuya, H., Reitz,
M., Cohen, J.C. and Broder, S. (1987) Proc. Natl. Acad. Sci.
USA 84, 7706^7710.
[23] Li, G., Lisziewicz, J., Sun, D., Zon, G., Dae£er, S., Wong-Staal,
F., Gallo, R.C. and Klotman, M.E. (1993) J. Virol. 67, 6882^
6888.
[24] Nakashima, H., Shoji, Y., Kim, S.G., Shimada, J., Mizushima,
Y., Ito, M., Yamamoto, N. and Takaku, H. (1994) Nucleic Acids
Res. 22, 5004^5010.
[25] Anazodo, M.I., Wainberg, M.A., Friesen, A.D. and Wright, J.A.
(1995) J. Virol. 69, 1794^1801.
[26] Sereni, D.R. (1999) J. Clin. Pharmacol. 39, 47^54.
FEBS 26461 11-9-02 Cyaan Magenta Geel Zwart
T. Inagawa et al./FEBS Letters 528 (2002) 48^52 51
[27] Kabanov, A.V., Vinogradov, S.V., Ovcharenko, A.V., Krivonoc,
A.V., Melik-Nubarov, N.S., Kiselev, V.I. and Severin, E.S.
(1990) FEBS Lett. 59, 327^330.
[28] Leiter, J.M., Agrawal, S., Palese, P. and Zamecnik, P.C. (1990)
Proc. Natl. Acad. Sci. USA 87, 3430^3434.
[29] Hata, T., Nakagawa, Y., Takai, K., Nakada, S., Yokota, T. and
Takaku, H. (1996) Biochem. Biophys. Res. Commun. 223, 341^
346.
[30] Mizuta, T., Fujiwara, M., Hatta, T., Abe, T., Miyano-Kurosaki,
N., Shigeta, S., Yokota, T. and Takaku, H. (1999) Nat. Biotech-
nol. 17, 583^587.
[31] Mizuta, T., Fujiwara, M., Abe, T., Miyano-Kurosaki, N., Yoko-
ta, T., Shigeta, S. and Takaku, H. (2000) Biochem. Biophys. Res.
Commun. 279, 158^161.
[32] Kuwasaki, T., Hosono, K., Takai, K., Ushijima, K., Nakashima,
H., Saito, T., Yamamoto, N. and Takaku, H. (1996) Biochem.
Biophys. Res. Commun. 228, 623^631.
[33] Hiratou, T., Tsukahara, S., Miyano-Kurosaki, N., Takai, K.,
Yamamoto, N. and Takaku, H. (1999) FEBS Lett. 456, 186^190.
[34] Shibahara, S., Muaki, S., Morisawa, H., Nakashima, H., Ko-
bayashi, as. and Yamanoto, N. (1989) Nucleic Acids Res. 17,
239^252.
[35] Koziolkiewicz, M., Krakowiak, A., Kwinkowski, M., Boczkow-
ska, M. and Stec, W.J. (1995) Nucleic Acids Res. 23, 5000^5005.
FEBS 26461 11-9-02 Cyaan Magenta Geel Zwart
T. Inagawa et al./FEBS Letters 528 (2002) 48^5252
